Small molecule · Inhibitor of topoisomerase I (TOP1) · developed by Achieve Life Sciences
Tenifatecan (SN2310) is a lipophilic emulsion of SN-38, a topoisomerase I inhibitor, covalently linked to tocopherol via a succinate linker. After in vivo hydrolysis, SN-38 stabilizes topoisomerase I-DNA complexes, inhibiting DNA religation and inducing double-stranded DNA breaks that trigger apoptosis. It is studied in breast, colorectal, pancreatic, pelvic, and lung cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00385177 | Phase 1 | Breast Neoplasms | Completed | ACHV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast NeoplasmsColorectal NeoplasmsLung NeoplasmsPancreatic NeoplasmsPelvic Neoplasms
Updated Oct 3, 2026. Something wrong or missing? Report it on the ACHV page.
See ACHV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACHV catalysts and pipeline →